Business
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Exclusivity Extended into December 2042KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity
About this update from Cingulate Inc.
Exclusivity Extended into December 2042 KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The patent, issued by the United States Patent and Trademark Office (USPTO) on June 16, 2026, as U.S. Patent No. 12,653,791, protects key aspects of CTx-1301’s formulation and method of use through December 2042, further strengthening Cingulate’s intellectual property portfolio surrounding its PTR™ platform. The issuance marks the first U.S. patent owned wholly by Cingulate covering CTx-1301 and further strengthens the company’s long-term intellectual property position as it advances toward potential commercialization. Titled “Trimodal, Precision-Timed Pulsatile Release Tablet,” the patent includes composition-of-matter, formulation, structural and method-of-treatment claims covering CTx-1301’s trimodal Precision Timed Release™ tablet technology. The patented design enables medication release in three distinct phases throughout the day from a single daily dose and protects key aspects of the tablet’s architecture, release mechanisms and therapeutic use. “This patent represents another important milestone in protecting the technology that differentiates CTx-1301 and underpins our proprietary Precision Timed Release™ Platform,” said Cingulate CEO Shane J. Schaffer. “As we advance toward potential commercialization, strengthening our intellectual property portfolio enhances the long-term value of CTx-1301 while supporting our goal of delivering consistent symptom control throughout the entire active day from a single daily dose.” In addition to the U.S. patent, Cingulate currently holds patents in 30 European territories, including the United Kingdom, as well as in Australia, Canada and Israel. The company also has patent applications pending in Hong Kong and the Republic of Korea. Cingulate is developing CTx-1301 and CTx-1302 as once-daily treatments for ADHD, with the goal of providing symptom control throughout the full active day. Furthermore,&nb...